POGLUT2

Across TCGA pan-cancer cohorts, POGLUT2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated POGLUT2 data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher POGLUT2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated POGLUT2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LSCC, PDAC, and UCEC are the cancer types where POGLUT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.658	0.935	.001	24	view →
PDAC	DFS	Tertile	III,IV	0.456	0.956	<.001	23	view →
UCEC	OS	Quartile	III,IV	0.380	1.000	.027	4	view →
GBM	DFS	Tertile	All	0.269	0.492	.008	4	view →
HNSC	DFS	Median	IV	0.558	0.761	.049	1	view →
LUAD	DFS	Quartile	III,IV	1.000	0.851	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

POGLUT2–LSCC (DFS)

Open the LSCC breakdown →